GlassScriptPhysician profile
Vincent J Maddela
NPI 1851430797
$2,979.13
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $904 · 2021: $1,164 · 2022: $335.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $660.73 | 2019-2021 | |
| Abbvie INC. | $372.77 | 2019-2022 | |
| Amarin Pharma, INC. | $345.75 | 2020-2021 | |
| Baxter Healthcare | $311.25 | 2022 | |
| Amgen INC. | $241.17 | 2020-2021 | |
| Lilly USA, LLC | $220.03 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $190.31 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.40 | 2019-2021 | |
| Pfizer INC. | $101.10 | 2019-2020 | |
| Astellas Pharma US INC | $67.50 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.90 | 2020 | |
| Shire North American Group INC | $36.28 | 2019 | |
| Dynavax Technologies Corporation | $34.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.98 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.19 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $23.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $20.21 | 2021 | |
| Ibsa Pharma INC. | $18.84 | 2020 | |
| Boston Scientific Corporation | $17.45 | 2019 | |
| Electromed, INC. | $12.18 | 2021 | |
| Allergan, INC. | $10.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Maddela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.